M Pascal Selected Research

Sodium

10/2000

Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Pascal Research Topics

Disease

6	Hypersensitivity (Allergy) 07/2022 - 10/2012
4	Anaphylaxis (Anaphylactic Shock) 07/2022 - 05/2011
2	Shellfish Hypersensitivity 09/2021 - 06/2017
2	Egg Hypersensitivity (Egg Allergy) 04/2014 - 10/2013
2	Shock 08/2013 - 05/2012
2	Food Hypersensitivity (Food Allergy) 01/2013 - 10/2012
1	Chronic Urticaria 02/2022
1	Mast Cell Activation Syndrome 12/2021
1	COVID-19 01/2021
1	Asthma (Bronchial Asthma) 04/2020
1	Nut Hypersensitivity (Nut Allergy) 07/2016
1	Brain Death (Brain Dead) 08/2013
1	Wounds and Injuries (Trauma) 08/2013
1	Persistent Vegetative State (Vegetative State) 08/2013
1	Traumatic Brain Injuries (Traumatic Brain Injury) 08/2013
1	Spinal Cord Injuries (Spinal Cord Injury) 08/2013
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 08/2013
1	Stroke (Strokes) 08/2013
1	Pulmonary Embolism 08/2013
1	Quadriplegia (Spastic Quadriplegia) 08/2013
1	Seasonal Allergic Rhinitis (Hay Fever) 10/2012
1	Thrombocytopenia (Thrombopenia) 05/2012
1	Hypoglycemia (Reactive Hypoglycemia) 05/2012
1	Sepsis (Septicemia) 05/2012
1	Anxiety Disorders (Anxiety Disorder) 01/2002
1	Heart Failure 01/2002
1	Inappropriate ADH Syndrome (SIADH) 01/2002
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2002
1	Neoplasms (Cancer) 01/2002
1	Fibrosis (Cirrhosis) 10/2000
1	Ascites 10/2000
1	Schistosomiasis (Bilharziasis) 01/2000
1	Infections 01/2000

Drug/Important Bio-Agent (IBA)

7	Immunoglobulin E (IgE)IBA 02/2022 - 10/2012
4	AllergensIBA 09/2021 - 10/2012
2	lipid transfer protein (glycolipid transfer protein)IBA 07/2022 - 01/2016
2	VaccinesIBA 01/2021 - 01/2013
1	Omalizumab (Xolair)FDA Link 02/2022
1	Tryptases (Tryptase)IBA 12/2021
1	Dermatophagoides pteronyssinus antigen p 2IBA 04/2020
1	Pyridinolcarbamate (P23)IBA 04/2020
1	Dermatophagoides pteronyssinus antigen p 1IBA 04/2020
1	Proteins (Proteins, Gene)FDA Link 07/2016
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2016
1	acetylsalicylic acid lysinateIBA 01/2016
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2016
1	valdecoxib (Bextra)FDA Link 01/2016
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2016
1	CrizotinibIBA 01/2015
1	Peptides (Polypeptides)IBA 01/2013
1	hypoxanthine arabinoside (ara-H)IBA 01/2013
1	HLA-DR Antigens (HLA-DR)IBA 01/2013
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2013
1	Profilins (Profilin)IBA 10/2012
1	Pharmaceutical PreparationsIBA 05/2012
1	Lactic Acid (Lactate)FDA LinkGeneric 05/2012
1	Lipoproteins (Lipoprotein)IBA 05/2011
1	1- (5- chloro- 1- ((2,4- dimethoxyphenyl)sulfonyl)- 3- (2- methoxyphenyl)- 2- oxo- 2,3- dihydro- 1H- indol- 3- yl)- 4- hydroxy- N,N- dimethyl- 2- pyrrolidinecarboxamideIBA 01/2002
1	2-oxindole (oxindole)IBA 01/2002
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2002
1	Vasopressins (Vasopressin)IBA 01/2002
1	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2002
1	mozavaptanIBA 10/2000
1	niravolineIBA 10/2000
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 10/2000
1	SodiumIBA 10/2000
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2000
1	Biomarkers (Surrogate Marker)IBA 01/2000
1	AntioxidantsIBA 01/2000

Therapy/Procedure

1	Therapeutics 12/2021
1	Resuscitation 08/2013
1	Artificial Respiration (Mechanical Ventilation) 05/2012
1	Length of Stay 05/2012
1	Continuous Renal Replacement Therapy 05/2012
1	Hemodiafiltration 05/2012
1	Oral Administration 10/2000